T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024
T2 Biosystems (NASDAQ:TTOO), a leader in rapid sepsis pathogen and antibiotic resistance gene detection, has announced its second quarter 2024 financial results and business updates will be reported on July 29, 2024, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
T2 Biosystems (NASDAQ:TTOO), a leader in rapid sepsis pathogen and antibiotic resistance gene detection, has announced its second quarter 2024 financial results and business updates will be reported on July 29, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day.
Investors can access the call by dialing 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 109834. A live and archived webcast will also be available on the company's website in the Investors section under Events & Presentations.
Details
News Market Reaction – TTOO
The recorded move for TTOO in the trading session of this news was -1.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024.
Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 109834, approximately ten to five minutes prior to the start time.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.